3 hours Ago By ABMN Staff
KBC Group NV lessened its position in Neurocrine Biosciences, Inc. ( NASDAQ:NBIX – Free Report ) by 24.5% in the fourth quarter, HoldingsChannel.
com reports. The fund owned 14,330 shares of the company’s stock after selling 4,642 shares during the period. KBC Group NV’s holdings in Neurocrine Biosciences were worth $1,957,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors also recently modified their holdings of the company. Plato Investment Management Ltd grew its position in shares of Neurocrine Biosciences by 2,481.9% in the 3rd quarter.
Plato Investment Management Ltd now owns 10,973 shares of the company’s stock valued at $1,263,000 after acquiring an additional 10,548 shares during the period. Swiss National Bank boosted its holdings in shares of Neurocrine Biosciences by 1.4% during the 3rd quarter.
Swiss National Bank now owns 298,700 shares of the company’s stock worth $34,416,000 after buying an additional 4,100 shares during the period. Tri Ri Asset Management Corp bought a new stake in shares of Neurocrine Biosciences during the 3rd quarter worth about $3,236,000. China Universal Asset Management Co.
Ltd. boosted its holdings in shares of Neurocrine Biosciences by 64.3% during the 3rd quarter.
China Universal Asset Management Co. Ltd. now owns 19,421 shares of the company’s stock worth $2,238,000 after buying an additional 7,597 shares during the period.
Finally, Victory Capital Management Inc. boosted its holdings in shares of Neurocrine Biosciences by 48.5% during the 3rd quarter.
Victory Capital Management Inc. now owns 204,205 shares of the company’s stock worth $23,529,000 after buying an additional 66,662 shares during the period. Institutional investors own 92.
59% of the company’s stock. Neurocrine Biosciences Price Performance NBIX stock opened at $151.82 on Friday.
The company has a 50 day simple moving average of $136.97 and a 200 day simple moving average of $131.51.
The stock has a market cap of $15.37 billion, a price-to-earnings ratio of 40.70 and a beta of 0.
33. Neurocrine Biosciences, Inc. has a 1 year low of $110.
95 and a 1 year high of $157.98. Insider Buying and Selling Analyst Upgrades and Downgrades Several analysts recently commented on NBIX shares.
Piper Sandler reaffirmed an “overweight” rating and set a $160.00 target price on shares of Neurocrine Biosciences in a report on Monday, December 23rd. StockNews.
com downgraded shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. Wedbush reissued an “outperform” rating and issued a $148.00 price objective on shares of Neurocrine Biosciences in a report on Monday, December 16th.
Raymond James reissued an “outperform” rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, October 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $190.
00 price objective on shares of Neurocrine Biosciences in a report on Monday, December 16th. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.
com, the stock has an average rating of “Moderate Buy” and an average price target of $166.10. Check Out Our Latest Stock Report on Neurocrine Biosciences Neurocrine Biosciences Company Profile ( Free Report ) Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally.
The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Featured Stories Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc.
( NASDAQ:NBIX – Free Report ). Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter .
.
